Abstract
Nitric oxide (NO) exerts its function in several cell and organ compartments. Recently, several lines of evidence have been accrued showing that NO can play a critical role in oncogenesis. Here we summarize some of these findings and highlight the role of NO as a possible target for antineoplastic drugs. Specifically, NO appears to affect some aspects of neuronal tumour progression, particularly the chemoresistance phenotype, through inhibition of MYC activity and expression of a large set of ATP binding cassette transporters. Here we provide lines of evidence supporting the view that MYCN can alter expression of several members of the ABC transporter family thus influencing the chemoresistance phenotype of neuroblastoma cells. Furthermore, we show that increased intracellular NO concentration either through addition of NO donors to culture medium or through forced expression of nNOS in neuroblastoma cells leads to decreased expression of MYCN and ABC drug transporter genes. Overall, data reviewed here and novel results presented, unveil a NO-MYCN-ABC transporters axis with important implication on development and control of the chemoresistance phenotype in neuronal tumours.
Keywords: MYCN, nitric oxide, ABC transporter genes, neuronal tumours, neuroblastoma
Current Pharmaceutical Design
Title: Nitric Oxide Control of MYCN Expression and Multi Drug Resistance Genes in Tumours of Neural Origin
Volume: 16 Issue: 4
Author(s): Antonio Porro, Christophe Chrochemore, Francesco Cambuli, Nunzio Iraci, Antonio Contestabile and Giovanni Perini
Affiliation:
Keywords: MYCN, nitric oxide, ABC transporter genes, neuronal tumours, neuroblastoma
Abstract: Nitric oxide (NO) exerts its function in several cell and organ compartments. Recently, several lines of evidence have been accrued showing that NO can play a critical role in oncogenesis. Here we summarize some of these findings and highlight the role of NO as a possible target for antineoplastic drugs. Specifically, NO appears to affect some aspects of neuronal tumour progression, particularly the chemoresistance phenotype, through inhibition of MYC activity and expression of a large set of ATP binding cassette transporters. Here we provide lines of evidence supporting the view that MYCN can alter expression of several members of the ABC transporter family thus influencing the chemoresistance phenotype of neuroblastoma cells. Furthermore, we show that increased intracellular NO concentration either through addition of NO donors to culture medium or through forced expression of nNOS in neuroblastoma cells leads to decreased expression of MYCN and ABC drug transporter genes. Overall, data reviewed here and novel results presented, unveil a NO-MYCN-ABC transporters axis with important implication on development and control of the chemoresistance phenotype in neuronal tumours.
Export Options
About this article
Cite this article as:
Porro Antonio, Chrochemore Christophe, Cambuli Francesco, Iraci Nunzio, Contestabile Antonio and Perini Giovanni, Nitric Oxide Control of MYCN Expression and Multi Drug Resistance Genes in Tumours of Neural Origin, Current Pharmaceutical Design 2010; 16 (4) . https://dx.doi.org/10.2174/138161210790232112
DOI https://dx.doi.org/10.2174/138161210790232112 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cordycepin in Anticancer Research: Molecular Mechanism of Therapeutic Effects
Current Medicinal Chemistry Self-Assembling Peptides: Potential Role in Tumor Targeting
Current Pharmaceutical Biotechnology Novel Ferulic Acid-donepezil Hybrids as Multifunctional Agents for th e Treatment of Alzheimer’s Disease with Butyrylcholinesterase, Amyloid- β, Antioxidant and Neuroprotective Properties
Letters in Drug Design & Discovery Prolyl-Specific Peptidases and Their Inhibitors in Biological Processes
Current Chemical Biology Targeting Mitochondria in Fighting Cancer
Current Pharmaceutical Design Neuronal Nicotinic Receptors and Neuroprotection: Newer Ligands May Help us Understand their Role in Neurodegeneration
Medicinal Chemistry Reviews - Online (Discontinued) The Epithelial-Mesenchymal Transition and Cancer Stem Cells: Functional and Mechanistic Links
Current Pharmaceutical Design Epigenetic Regulation of ABCB1 Transporter Expression and Function
Current Pharmacogenomics and Personalized Medicine Role of FK506 Binding Proteins in Neurodegenerative Disorders
Current Medicinal Chemistry Molecular Pharmacology of Malignant Pleural Mesothelioma: Challenges and Perspectives From Preclinical and Clinical Studies
Current Drug Targets Cellular Delivery In Vivo of siRNA-Based Therapeutics
Current Pharmaceutical Design Potential Role of (-)-Epigallocatechin-3-Gallate (EGCG) in the Secondary Prevention of Alzheimer Disease
Current Drug Targets Can Dietary Antioxidants Reduce the Incidence of Brain Tumors?
Current Drug Metabolism c-Myc and Downstream Targets in the Pathogenesis and Treatment of Cancer
Recent Patents on Anti-Cancer Drug Discovery Hemoglobin Neurotoxicity is Attenuated by Inhibitors of the Protein Kinase CK2 Independent of Heme Oxygenase Activity
Current Neurovascular Research Therapeutic microRNA Delivery Strategies with Special Emphasis on Cancer Therapy and Tumorigenesis: Current Trends and Future Challenges
Current Drug Metabolism Role of the Insulin Receptor Variant Forms in Human Metabolic Disorders
Current Genomics Pharmacological Inhibition of Hsp90 as a Novel Antitumor Strategy to Target Cytoarchitecture Through Extracellular Matrix Signaling
Medicinal Chemistry Nutritional and Medical Applications of Spirulina Microalgae
Mini-Reviews in Medicinal Chemistry Recent Multi-target Approaches on the Development of Anti- Alzheimer's Agents Integrating Metal Chelation Activity
Current Medicinal Chemistry